title: What people want from sex and preexposure prophylaxis.
abstract: OBJECTIVE
  As demand for preexposure prophylaxis (PrEP) increases, we are learning more about what people want from sex and PrEP.
  
  
  RESULTS
  PrEP demand has reached a tipping point in the USA and is increasing rapidly. Although the primary benefit of PrEP use is biological, to reduce risk of HIV infection, PrEP users often express an alternative set of social and emotional benefits that are provided by PrEP. These collateral benefits of PrEP have salience, affect, and are experienced in the present, which are compelling drivers of human behavior. PrEP use has been associated with feeling safe during sex, usually in contrast to ruminations related to fear of HIV or intimate partner violence or control. PrEP can create empowerment, or agency, defined as the capacity and autonomy to act on one's own behalf, because it provides control over one's vulnerability to HIV and relief to women and men who may otherwise worry about whether their partners will use a condom, take antiretroviral therapy, or disclose their HIV status accurately. Planning for sexual and social goals in calm moments is also empowering. These highly desired collateral benefits of PrEP could be undermined, or eliminated, if PrEP is implemented in ways that are coercive or that foment fear of sexual risk compensation, drug resistance, toxicity, or moral judgment.
  
  
  CONCLUSIONS
  Current PrEP implementation provides direct and indirect benefits that are highly desired.
authors.affiliation: aGladstone Institutes bUniversity of California cSan Francisco AIDS Foundation, San Francisco, California, USA.
authors.forename: Robert M
authors.initials: RM
authors.lastname: Grant
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Koester
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D018890:Chemoprevention / Q000379:methods* / Q000523:psychology; D018562:Disease Transmission, Infectious / Q000517:prevention & control*; D000068679:Emtricitabine / Q000008:administration & dosage; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000523:psychology* / Q000635:transmission; D006801:Humans; D008297:Male; D065129:Pre-Exposure Prophylaxis / Q000379:methods*; D021841:Safe Sex / Q000523:psychology*; D000068698:Tenofovir / Q000008:administration & dosage; D014481:United States
chemical_list: D019380:Anti-HIV Agents; D000068698:Tenofovir; D000068679:Emtricitabine